Holen Sie sich die Stockscreener-App
2.03
0.00%
0.00
Handel nachbörslich:
2.04
0.01
+0.49%
Schlusskurs vom Vortag:
$2.03
Offen:
$2.03
24-Stunden-Volumen:
9,534
Relative Volume:
0.26
Marktkapitalisierung:
$23.50M
Einnahmen:
$3.35M
Nettoeinkommen (Verlust:
$86,000
KGV:
131.82
EPS:
0.0154
Netto-Cashflow:
$2.67M
1W Leistung:
-1.46%
1M Leistung:
-8.14%
6M Leistung:
-6.02%
1J Leistung:
+81.25%
1-Tages-Spanne:
$2.02
$2.0563
1-Wochen-Bereich:
$2.02
$2.11
52-Wochen-Spanne:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.03 | 23.96M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Cash Flow - TradingKey
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD, Inc. Revenue Breakdown – MUN:29TA - TradingView
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.060| - TradingKey
TherapeuticsMD (TXMD) Holds Steady at $2.06 as Consolidation ContinuesPut Support - dars.gov.et
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Company Profile & Introduction - Moomoo
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Ongoing ChallengesEarnings Call Highlights - DonanımHaber
TherapeuticsMD (TXMD) News Flow - Moomoo
TherapeuticsMD (TXMD) Edges Higher, Consolidating Near $2.00New Highs New Lows - dars.gov.et
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Highlights Ongoing Revenue ChallengesReturn On Capital - dars.gov.et
TXMD Q3 2023 Earnings: Significant EPS Miss as Company Faces Operational ChallengesEarnings Risk Report - dars.gov.et
TherapeuticsMD (TXMD) Rallies 3.94% as Stock Approaches Key Resistance at $2.22Stop Run - dars.gov.et
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
Enterprise value to revenue forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc (TXMD) Institutional Confidence - TradingKey
TherapeuticsMD Inc (TXMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TXMD Q3 2023 Earnings: EPS Misses Estimates Amid Continued Cash BurnNet Income Trends - newsline.com
TherapeuticsMD (TXMD) Gains 3.64%, Tests Resistance at $2.39High Low Breadth - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates Sharply, Yet Stock Surges 20.9%EPS Surprise History - newsline.com
TXMD Q3 2023 Earnings: Wider-than-Expected Loss Highlights Operational ChallengesProfit Inflection Point - newsline.com
TherapeuticsMD (TXMD) Nears Support Amid Modest Selling PressureIndex Put Call - newsline.com
TherapeuticsMD Inc. (TXMD) Gains Ground as Shares Push Toward Resistance ZoneAAII Neutral - newsline.com
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Highlights Ongoing ChallengesEarnings Quality Score - dars.gov.et
TXMDTherapeuticsMD Inc Stock Price and Quote - Finviz
TXMD Q3 2023 Earnings: Deep EPS Miss Overshadowed by Strategic ProgressNegative Surprise Momentum - newsline.com
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Operational ChallengesTrough Earnings Signal - The Legal Advocate
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.08%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):